Drug intelligence / Profile preview

losartan + hydrochlorothiazide + amlodipine + spironolactone

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy consisting of four antihypertensive medications with complementary mechanisms of action. The combination includes: - Losartan: An angiotensin II receptor blocker (ARB) that works by blocking the vasoactive properties of angiotensin II - Hydrochlorothiazide (HCTZ): A thiazide diuretic that increases sodium and water excretion - Amlodipine: A calcium channel blocker (CCB) that relaxes blood vessels - Spironolactone: An aldosterone receptor antagonist that causes the kidneys to eliminate unneeded water and sodium while reducing potassium loss This quadruple therapy would likely be used for resistant hypertension cases where blood pressure cannot be adequately controlled with fewer agents.

02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on losartan + hydrochlorothiazide + amlodipine + spironolactone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan + hydrochlorothiazide + amlodipine + spironolactone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call